利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

36 records (took 0.027 seconds)

    MicroRNA-198 as a tumor suppressor in ovarian cancer
    4.
    发明授权
    MicroRNA-198 as a tumor suppressor in ovarian cancer 有权

    公开(公告)号：US12134769B2

    公开(公告)日：2024-11-05

    申请号：US17236851

    申请日：2021-04-21

    Applicant: Baylor College of Medicine

    Inventor： Qizhi Yao ,  Christian Marin-Muller ,  Changyi Chen

    IPC: C12N15/113 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  A61K51/00 ,  A61N5/10

    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.

    MicroRNA-198 as a tumor suppressor in ovarian cancer
    5.
    发明授权
    MicroRNA-198 as a tumor suppressor in ovarian cancer 有权

    公开(公告)号：US11008573B2

    公开(公告)日：2021-05-18

    申请号：US16299986

    申请日：2019-03-12

    Applicant: Baylor College of Medicine

    Inventor： Qizhi Yao ,  Christian Marin-Muller ,  Changyi Chen

    IPC: C12N15/113 ,  A61K31/7088 ,  A61K51/00 ,  A61K31/7105 ,  A61K31/713 ,  A61N5/10 ,  A61K45/06

    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.

    ANTAGONISTS OF MIR-196A
    9.
    发明申请
    ANTAGONISTS OF MIR-196A 审中-公开
    MIR-196A的拮抗剂

    公开(公告)号：US20130295160A1

    公开(公告)日：2013-11-07

    申请号：US13738742

    申请日：2013-01-10

    Applicant: Baylor College of Medicine ,  Gradalis, Inc.

    Inventor： Donald Rao ,  Zhaohui Wang ,  John J. Nemunaitis ,  Changyi Chen ,  Qizhi Yao

    IPC: C12N15/113 ,  A61K48/00

    CPC classification number: C12N15/1135 ,  A61K48/005 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2330/51

    Abstract: A miR-196a antagonist capable of inhibiting a miR-196a activity, the miR-196a antagonist comprising one or more target sites for miR-196a. Included is also an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more miR-196a antagonists capable of inhibiting a miR-196a activity. In one example, the one or more miR-196a antagonists comprise at least one stem-loop structure comprising a guide strand that comprises a sequence that is complementary to miR-196a, the stem-loop structure further comprising a passenger strand that comprises a mismatch.

    Abstract translation: 能够抑制miR-196a活性的miR-196a拮抗剂包含miR-196a的一个或多个靶位点的miR-196a拮抗剂。 包括的还包括与启动子可操作地连接的启动子和核酸插入物的表达载体，其中插入物编码能够抑制miR-196a活性的一种或多种miR-196a拮抗剂。 在一个实例中，所述一种或多种miR-196a拮抗剂包含至少一个包含引导链的茎 - 环结构，所述引导链包含与miR-196a互补的序列，所述茎 - 环结构进一步包括包含错配的乘客链 。

    MICRORNA-198 AS A TUMOR SUPPRESSOR IN OVARIAN CANCER
    10.
    发明申请
    MICRORNA-198 AS A TUMOR SUPPRESSOR IN OVARIAN CANCER 有权

    公开(公告)号：US20220177889A1

    公开(公告)日：2022-06-09

    申请号：US17236851

    申请日：2021-04-21

    Applicant: Baylor College of Medicine

    Inventor： Qizhi Yao ,  Christian Marin-Muller ,  Changyi Chen

    IPC: C12N15/113 ,  A61K31/7088 ,  A61K45/06 ,  A61K51/00 ,  A61K31/7105 ,  A61K31/713 ,  A61N5/10

    Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual

Patent Agency Ranking